Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2018

View Archived Issues

La Jolla Pharmaceutical treats first patient in Giapreza pediatric study

Arrowhead Pharmaceuticals cleared to begin clinical trial of ARO-AAT in New Zealand

FDA clears IND for MabSpace Biosciences' next-generation PD-L1 antibody

Apellis Pharmaceuticals reports updated data from FILLY study of APL-2

Kite and Sangamo Therapeutics collaborate to develop next-generation cell therapies for cancer

Preliminary phase II results show activity of tipifarnib in head and neck cancer

Apatinib active in patients with adenoid cystic carcinoma of the head and neck

Accutar Biotechnology describes new proteolysis-targeting chimera compounds

Xofluza approved in Japan for treatment of influenza types A and B

Max-Delbrueck-Centrum, Forschungsverbund Berlin patent novel tryptophan 5-hydroxylase inhibitors

Novel parkin activators identified at the Mayo Foundation for Medical Education and Research

Kitasato Institute and collaborators divulge novel delta-opioid receptor agonists

FDA grants priority review to lanadelumab BLA for HAE

Basilea initiates phase III study of ceftobiprole in ABSSSI

Frequency Therapeutics receives grant from JDRF

Hetero Labs presents novel HIV inhibitors

Novo Nordisk reports topline results from PIONEER 1 trial of oral semaglutide in type 2 diabetes

Daiichi Sankyo begins clinical testing of DS-1062 for NSCLC

JHL Biotech set to begin phase I study of bevacizumab biosimilar

Kallyope raises USD 66 million in series B financing

Corcept announces interim phase II results for relacorilant in patients with hypercortisolism

New model of Alzheimer's disease reveals potential of NAD+ treatment

Tell us about your experience with TRDN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...